Qi Xinran, Ji Han, Bianchi Enrica, Hall Susan J, Avellino Gabriella, Berg William, Bearelly Priyanka, Sigman Mark, Wu Zhijin, Spade Daniel J
Department of Pathology and Laboratory Medicine, Brown University, Providence, Rhode Island, USA.
Department of Biostatistics, Brown University, Providence, Rhode Island, USA.
Andrology. 2025 May 10. doi: 10.1111/andr.70060.
Approximately half of male factor infertility cases are idiopathic, indicating a need for new methods to supplement male fertility assessment.
The objective of this study was to identify differences in the sperm transcriptomes of men with different clinical fertility status. We hypothesized that sperm mRNA profiling could distinguish men presenting for fertility assessment from proven fertile men.
We compared two groups of study participants: men who presented for infertility assessment (n = 53, "infertility"), and men without a history of infertility who had fathered a child and were presenting for vasectomy (n = 14, "proven fertile" control). Study participants provided a semen sample for semen analysis and sperm mRNA sequencing. Differentially abundant genes were identified, and a gene expression summary score was constructed to test the ability of RNA-seq data to differentiate between study populations.
The semen parameter that best differentiated between study populations was motility (area under the ROC curve = 0.746). In RNA-seq analysis, 1885 total differentially abundant transcripts were identified (q < 0.05, fold difference ≥ 2), 1004 (53.3%) of which were downregulated in infertility study participants. The Gene Ontology term, spermatogenesis, was enriched, with 40 out of 44 differentially abundant genes downregulated in infertility study participants. A gene expression summary score consisting of 100 upregulated and 100 downregulated genes was able to differentiate between the two groups of study participants.
Sperm mRNAs differed between proven fertile and infertility study men. Known fertility-associated genes, including PRM1 and PRM2, and potentially novel fertility markers, including HOOK1 and SPATA6, were downregulated in infertility study samples. Future studies should test these results for reproducibility and test whether novel biomarker candidates can provide mechanistic information about etiologies of idiopathic male infertility.
Our results support the hypothesis that sperm mRNA abundance differs by clinical fertility status.
约一半的男性因素不育病例病因不明,这表明需要新的方法来补充男性生育力评估。
本研究的目的是确定不同临床生育状态男性精子转录组的差异。我们假设精子mRNA谱分析能够区分前来进行生育力评估的男性与已证实具有生育能力的男性。
我们比较了两组研究参与者:前来进行不育评估的男性(n = 53,“不育组”),以及没有不育史且育有子女并前来进行输精管切除术的男性(n = 14,“已证实具有生育能力”对照组)研究参与者提供精液样本用于精液分析和精子mRNA测序。鉴定出差异丰度基因,并构建基因表达汇总评分以测试RNA测序数据区分研究人群的能力。
在研究人群之间差异最显著的精液参数是活力(ROC曲线下面积 = 0.746)。在RNA测序分析中,共鉴定出了1885个差异丰度转录本(q < 0.05,倍数差异≥2),其中1004个(53.3%)在不育组研究参与者中表达下调。基因本体术语“精子发生”显著富集,在不育组研究参与者中,44个差异丰度基因中有40个表达下调。由100个上调基因和100个下调基因组成的基因表达汇总评分能够区分两组研究参与者。
已证实具有生育能力的男性与不育组男性的精子mRNA存在差异。在不育组研究样本中,已知与生育相关的基因,包括PRM1和PRM2,以及潜在的新型生育标志物,包括HOOK1和SPATA6,均表达下调。未来的研究应检验这些结果的可重复性,并测试新型生物标志物候选物是否能够提供关于特发性男性不育病因的机制信息。
我们的结果支持以下假设,即精子mRNA丰度因临床生育状态而异。